Preventive and Therapeutic Effects of MG132 by Activating Nrf2-ARE Signaling Pathway on Oxidative Stress-Induced Cardiovascular and Renal Injury

被引：27

作者：

Cui, Wenpeng ^{[1
,2
]}

Bai, Yang ^{[2
,3
]}

Luo, Ping ^{[1
]}

Miao, Lining ^{[1
]}

Cai, Lu ^{[2
]}

机构：

[1] Jilin Univ, Hosp 2, Dept Nephrol, Changchun 130041, Jilin Province, Peoples R China

[2] Univ Louisville, Dept Pediat, KCHRI, Louisville, KY 40202 USA

[3] Peoples Hosp Jilin Prov, Dept Cardiol, Changchun 130021, Peoples R China

来源：

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY | 2013年 / 2013卷

基金：

中国国家自然科学基金;

关键词：

UBIQUITIN-PROTEASOME SYSTEM; ANTIOXIDANT RESPONSE ELEMENT; NF-KAPPA-B; AS4.1 JUXTAGLOMERULAR CELLS; TRANSCRIPTION FACTOR NRF2; CHRONIC KIDNEY-DISEASE; ENDOTHELIAL DYSFUNCTION; HEME OXYGENASE-1; GENE-EXPRESSION; INFLAMMATORY RESPONSE;

D O I：

10.1155/2013/306073

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

So far, cardiovascular and renal diseases have brought us not only huge economic burden but also serious society problems. Since effective therapeutic strategies are still limited, to find new methods for the prevention or therapy of these diseases is important. Oxidative stress has been found to play a critical role in the initiation and progression of cardiovascular and renal diseases. In addition, activation of nuclear-factor-E2-related-factor-2- (Nrf2-) antioxidant-responsive element (ARE) signaling pathway protects cells and tissues from oxidative damage. As a proteasomal inhibitor, MG132 was reported to activate Nrf2 expression and function, which was accompanied with significant preventive and/or therapeutic effect on cardiovascular and renal diseases under most conditions; therefore, MG132 seems to be a potentially effective drug to be used in the prevention of oxidative damage. In this paper, we will summarize the information available regarding the effect of MG132 on oxidative stress-induced cardiovascular and renal damage, especially through Nrf2-ARE signaling pathway.

引用

页数：10

共 131 条

[1] The proteasome: structure, function, and role in the cell [J].

Adams, J .

CANCER TREATMENT REVIEWS, 2003, 29 :3-9

[2] Oxidative Stress-Mediated Regulation of Proteasome Complexes [J].

Aiken, Charity T. ;

Kaake, Robyn M. ;

Wang, Xiaorong ;

Huang, Lan .

MOLECULAR & CELLULAR PROTEOMICS, 2011, 10 (05)

[3] Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway [J].

Alam, J ;

Cook, JL .

CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (30) :2499-2511

[4] Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage [J].

Andreassi, MG .

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2003, 543 (01) :67-86

[5]

[Anonymous], 2005, Indian J Med Sci, V59, P463

[6] Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins [J].

Ansar, Sameer ;

Koska, Juraj ;

Reaven, Peter D. .

CARDIOVASCULAR DIABETOLOGY, 2011, 10

[7] Impairment of Ubiquitin-Proteasome System by E334K cMyBPC Modifies Channel Proteins, Leading to Electrophysiological Dysfunction [J].

Bahrudin, Udin ;

Morikawa, Kumi ;

Takeuchi, Ayako ;

Kurata, Yasutaka ;

Miake, Junichiro ;

Mizuta, Einosuke ;

Adachi, Kaori ;

Higaki, Katsumi ;

Yamamoto, Yasutaka ;

Shirayoshi, Yasuaki ;

Yoshida, Akio ;

Kato, Masahiko ;

Yamamoto, Kazuhiro ;

Nanba, Eiji ;

Morisaki, Hiroko ;

Morisaki, Takayuki ;

Matsuoka, Satoshi ;

Ninomiya, Haruaki ;

Hisatome, Ichiro .

JOURNAL OF MOLECULAR BIOLOGY, 2011, 413 (04) :857-878

[8] A Proteasome Inhibitor-stimulated Nrf1 Protein-dependent Compensatory Increase in Proteasome Subunit Gene Expression Reduces Polycomb Group Protein Level [J].

Balasubramanian, Sivaprakasam ;

Kanade, Santosh ;

Han, Bingshe ;

Eckert, Richard L. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (43) :36179-36189

[9] Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation [J].

Bhat, Kavita P. ;

Greer, Susanna F. .

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2011, 1809 (02) :150-155

[10] Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].

Boaz, M ;

Smetana, S ;

Weinstein, T ;

Matas, Z ;

Gafter, U ;

Iaina, A ;

Knecht, A ;

Weissgarten, Y ;

Brunner, D ;

Fainaru, M ;

Green, MS .

LANCET, 2000, 356 (9237) :1213-1218

← 1 2 3 4 5 6 7 8 9 10 →